Rituximab after a first episode of steroid-sensitive nephrotic syndrome in children
Tests rituximab against steroids alone in children with a first nephrotic syndrome episode.
Key facts
- Who runs it
- Children's Hospital of Fudan University
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Rituximab in the First Episode of Paediatric Nephrotic Syndrome
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 138 people, planned
- Started
- 1 Mar 2025
- Expected to end
- 28 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Rituximab
- Corticosteroid
- Record updated
- 22 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with a first episode of steroid-sensitive nephrotic syndrome who are now in remission. It compares one dose of rituximab plus prednisolone with prednisolone alone.
- Age
- 1 Year to 18 Years
- Sex
- All sexes can join.
- Disease stage
- First episode of steroid-sensitive nephrotic syndrome (a kidney disease with a lot of protein in the urine), in remission at study entry. Kidney function (eGFR) must be ≥90 ml/min per 1.73 m2.
- Earlier treatment
- No drugs that weaken the immune system in the 3 months before joining. Corticosteroids used for nephrotic syndrome are allowed.
- Biomarker or test result
- CD20 positive cells in the blood must be ≥1% of total lymphocytes.
Main reasons for not taking part
- Nephrotic syndrome caused by another disease (secondary NS)
- Abnormal blood tests, such as low white cells, low platelets, anemia, positive autoimmune tests or high liver values
- Severe or long-lasting infections in the past 6 months, such as tuberculosis, hepatitis B or C, HIV, EBV or CMV
- Live vaccine in the last month, or poorly controlled high blood pressure
- Autoimmune disease, primary immunodeficiency, tumor, or allergy to Rituximab
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Children between 1 and 18 years with Steroid-Sensitive Nephrotic Syndrome (nephrotic-range proteinuria and either hypoalbuminemia or edema when albumin level is not available)
- Estimated glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m2 at study entry
- Remission at study entry
- the cluster of differentiation antigen 20 (CD20) positive cells in peripheral blood ≥1% total lymphocytes
- No immunosuppressive agents have been used within 3 months of enrolment, except for the use of corticosteroid to treat nephrotic syndrome
- Provision of consent by a legal representative using a document approved by the institutional review board after receiving an adequate explanation of this clinical trial. For children ages 8-18, written assent is required using age-appropriate and background-appropriate documents
Who cannot take part
- Presence of severe or chronic infections within 6 months before assignment: tuberculosis or in whom tuberculosis is suspected; Epstein-Barr virus or cytomegalovirus; hepatitis B or hepatitis C or hepatitis B virus carrier, human immunodeficiency virus or other active viral infections
- Patients with poorly controlled hypertension
- Patients with severe brain, heart, liver, and other important organs, as well as blood and endocrine system diseases
- Presence or history of autoimmune diseases, primary immunodeficiency, or tumor
- Patients with a known allergy to Rituximab and its excipients
- Assessed to be unfit for participation by the investigators (patients highly likely to be lost to follow-up or provide inaccurate data, for example, patients with alcohol or other substance misuse disorders, and patients with psychological disorders)
- values: leukopenia (white blood cell count ≤3.0*109/L); moderate and severe anemia (hemoglobin <9.0g/dL); thrombocytopenia (platelet count <100*1012/ L); positivity of autoimmunity tests (ANA, Anti DNA antibody, ANCA) or reduced C3 levels; Alanine aminotransferase or aspartate aminotransferase > 2.5× upper limit of normal value
- Diagnosis of secondary NS
- Patients showing one of the following abnormal clinical laboratories
- Live vaccination within last month
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study will be a randomized, open-label trial in children with the initial episode of SSNS and whose state of complete remission after received standard prednisolone, to determine whether rituximab (a single intravenous infusion of 375 mg/m2) would be noninferior to corticosteroid alone in maintaining complete disease remission during 12-month of follow-up.
The 2 groups in the trial
- RituximabTreatment being tested
Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission. The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
Treatment: Rituximab and Corticosteroid
- Routine TherapyOther group
The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
Treatment: Corticosteroid
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Single-dose Rituximab Biosimilar in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial
- Plain-language title
- Rituximab after a first episode of steroid-sensitive nephrotic syndrome in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT05850546, who can take part
- Record updated
- 22 January 2025